<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002506</url>
  </required_header>
  <id_info>
    <org_study_id>070619</org_study_id>
    <nct_id>NCT03002506</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns</brief_title>
  <official_title>Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help provide information about how patients with burn handle two antibiotics&#xD;
      (ceftolozane and tazobactam) and use that information to guide dosing recommendations for&#xD;
      these patients. The 12 patients who complete the study will receive a single dose of 3 grams&#xD;
      ceftolozane/tazobactam intravenously. We will collect blood and urine samples to determine&#xD;
      how much of each antibiotic is in the body and urine at various times over a 24 hour period.&#xD;
      This information will be used with previously published information from microbiology&#xD;
      laboratories to perform simulations that will provide recommendations on optimal dosing&#xD;
      recommendations of these antibiotics in patients with burns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose pharmacokinetic study of ceftolozane and tazobactam will be conducted in&#xD;
      patients with burns at the Burn Center at University Medical Center. A total of 12 adults&#xD;
      aged 18 to 80 years with &gt;/= 20% percent total body surface area burned will be required to&#xD;
      complete the study. A single intravenous dose of ceftolozane and tazobactam of 2 grams/1 gram&#xD;
      will be administered over 60 minutes and whole blood will be obtained predose and at 0.5, 1,&#xD;
      1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours following the start of infusion. Urine samples&#xD;
      (5 ml) will be collected from a urine collection bag (if the patient has urinated) at the&#xD;
      following timepoints: 0-0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, and 12-24 hours for analysis of&#xD;
      ceftolozane and tazobactam content. Urine for collected during each time period will be&#xD;
      measured to determine urine volume for urine clearance calculations. The volume of urine in&#xD;
      the urine over the entire 24 hour period and an aliquot sent for analysis of urine creatinine&#xD;
      content to determine the patient's 24 hour creatinine clearance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Much slower recruitment than anticipated&#xD;
  </why_stopped>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftolozane Clearnace</measure>
    <time_frame>24 hours</time_frame>
    <description>Liters/hour (continuous values)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Burns</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>ceftolozane/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/tazobactam</intervention_name>
    <description>Single dose of 2 grams/1 gram intravenously administered over 60 minutes.</description>
    <arm_group_label>ceftolozane/tazobactam</arm_group_label>
    <other_name>Zerbaxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects, ages 18-80 years, of all racial and ethnic origins.&#xD;
&#xD;
          2. Non-English Spanish speakers will be included in the study.&#xD;
&#xD;
          3. We are recruiting 12 patients with thermal burn injuries (percent total body surface&#xD;
             area burned &gt;/= 20%). Patients will be at least five days from the date of the burn&#xD;
             injury.&#xD;
&#xD;
          4. Patients will have central venous or arterial line access.&#xD;
&#xD;
          5. Patients will be already be receiving standard of care antimicrobial therapy for a&#xD;
             suspected infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing or unwilling to use a reliable contraception method during the&#xD;
             study. The effects of ceftolozane and tazobactam on pregnancy are unknown. In&#xD;
             addition, the metabolic changes that accompany pregnancy may alter the&#xD;
             concentration-time profile of ceftolozane and tazobactam, so that the pregnancy and&#xD;
             post-partum state would be a confounding variable.&#xD;
&#xD;
          2. Abnormal liver function tests: transaminases &gt;10 times upper limit of normal, Alkaline&#xD;
             phosphatase &gt;5 times upper limit of normal, total bilirubin &gt;5 times upper limit of&#xD;
             normal.&#xD;
&#xD;
          3. History of allergies to beta-lactam antibiotics.&#xD;
&#xD;
          4. Patients unwilling to comply with study procedures.&#xD;
&#xD;
          5. Current or previous participation within 28 days of enrollment in another research&#xD;
             study that involves the use of medication, contrast, or any other compound that may&#xD;
             alter blood count and/or blood chemistry (liver function, kidney function or&#xD;
             electrolyte balance), unless waved by principal investigator (PI).&#xD;
&#xD;
          6. Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study&#xD;
             enrollment, unless waved by PI.&#xD;
&#xD;
          7. Creatinine clearance &lt; 30 ml/min as estimated by the Cockcroft-Gault equation.&#xD;
&#xD;
          8. Patients who are receiving piperazillin/tazobactam or have received&#xD;
             piperacillin/tazobactam within the past 48 hours.&#xD;
&#xD;
          9. Patients who are receiving vasopressors.&#xD;
&#xD;
         10. Patients with a total body weight &lt; 60 kg or &gt; 130 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald G Hall, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University HSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <results_first_submitted>October 19, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ceftolozane</keyword>
  <keyword>tazobactam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03002506/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ceftolozane/Tazobactam</title>
          <description>One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.&#xD;
Ceftolozane/tazobactam: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who provided informed consent and received ceftolozane/tazobactam.</population>
      <group_list>
        <group group_id="B1">
          <title>Ceftolozane/Tazobactam</title>
          <description>One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.&#xD;
Ceftolozane/tazobactam: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.67" spread="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ceftolozane Clearnace</title>
        <description>Liters/hour (continuous values)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.&#xD;
Ceftolozane/tazobactam: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Ceftolozane Clearnace</title>
          <description>Liters/hour (continuous values)</description>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>Adverse events were to be reported if reported by the participant, healthcare team member, research team member, or lab documented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ceftolozane/Tazobactam</title>
          <description>One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.&#xD;
Ceftolozane/tazobactam: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single-dose pharmacokinetic study. No clinical outcomes to evaluate efficacy. No safety data provided by this study beyond a single dose in this population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ronald Hall, PharmD, MSCS</name_or_title>
      <organization>Texas Tech UHSC</organization>
      <phone>214-358-9009</phone>
      <email>ronald.hall@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

